Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Mefenamic Acid Shows Neuroprotective Effects and Improves Cognitive Impairment in in Vitro and in Vivo Alzheimer's Disease Models

Yuyoung Joo, Hye-Sun Kim, Ran-Sook Woo, Cheol Hyoung Park, Ki-Young Shin, Jean-Pyo Lee, Keun-A Chang, Seonghan Kim and Yoo-Hun Suh
Molecular Pharmacology January 2006, 69 (1) 76-84; DOI: https://doi.org/10.1124/mol.105.015206
Yuyoung Joo
Department of Pharmacology, College of Medicine, National Creative Research Initiative Center for Alzheimer's Dementia and Neuroscience Research Institute, Medical Research Council, Seoul National University, Seoul, South Korea (Y.J., H.-S.K., R.-S.W., C.H.P., K.-Y.S., K.-A.C., S.K., Y.-H.S.); and Department of Pediatrics, School of Medicine, University of California at San Diego, La Jolla, California (J.-P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hye-Sun Kim
Department of Pharmacology, College of Medicine, National Creative Research Initiative Center for Alzheimer's Dementia and Neuroscience Research Institute, Medical Research Council, Seoul National University, Seoul, South Korea (Y.J., H.-S.K., R.-S.W., C.H.P., K.-Y.S., K.-A.C., S.K., Y.-H.S.); and Department of Pediatrics, School of Medicine, University of California at San Diego, La Jolla, California (J.-P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ran-Sook Woo
Department of Pharmacology, College of Medicine, National Creative Research Initiative Center for Alzheimer's Dementia and Neuroscience Research Institute, Medical Research Council, Seoul National University, Seoul, South Korea (Y.J., H.-S.K., R.-S.W., C.H.P., K.-Y.S., K.-A.C., S.K., Y.-H.S.); and Department of Pediatrics, School of Medicine, University of California at San Diego, La Jolla, California (J.-P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheol Hyoung Park
Department of Pharmacology, College of Medicine, National Creative Research Initiative Center for Alzheimer's Dementia and Neuroscience Research Institute, Medical Research Council, Seoul National University, Seoul, South Korea (Y.J., H.-S.K., R.-S.W., C.H.P., K.-Y.S., K.-A.C., S.K., Y.-H.S.); and Department of Pediatrics, School of Medicine, University of California at San Diego, La Jolla, California (J.-P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ki-Young Shin
Department of Pharmacology, College of Medicine, National Creative Research Initiative Center for Alzheimer's Dementia and Neuroscience Research Institute, Medical Research Council, Seoul National University, Seoul, South Korea (Y.J., H.-S.K., R.-S.W., C.H.P., K.-Y.S., K.-A.C., S.K., Y.-H.S.); and Department of Pediatrics, School of Medicine, University of California at San Diego, La Jolla, California (J.-P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Pyo Lee
Department of Pharmacology, College of Medicine, National Creative Research Initiative Center for Alzheimer's Dementia and Neuroscience Research Institute, Medical Research Council, Seoul National University, Seoul, South Korea (Y.J., H.-S.K., R.-S.W., C.H.P., K.-Y.S., K.-A.C., S.K., Y.-H.S.); and Department of Pediatrics, School of Medicine, University of California at San Diego, La Jolla, California (J.-P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keun-A Chang
Department of Pharmacology, College of Medicine, National Creative Research Initiative Center for Alzheimer's Dementia and Neuroscience Research Institute, Medical Research Council, Seoul National University, Seoul, South Korea (Y.J., H.-S.K., R.-S.W., C.H.P., K.-Y.S., K.-A.C., S.K., Y.-H.S.); and Department of Pediatrics, School of Medicine, University of California at San Diego, La Jolla, California (J.-P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seonghan Kim
Department of Pharmacology, College of Medicine, National Creative Research Initiative Center for Alzheimer's Dementia and Neuroscience Research Institute, Medical Research Council, Seoul National University, Seoul, South Korea (Y.J., H.-S.K., R.-S.W., C.H.P., K.-Y.S., K.-A.C., S.K., Y.-H.S.); and Department of Pediatrics, School of Medicine, University of California at San Diego, La Jolla, California (J.-P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoo-Hun Suh
Department of Pharmacology, College of Medicine, National Creative Research Initiative Center for Alzheimer's Dementia and Neuroscience Research Institute, Medical Research Council, Seoul National University, Seoul, South Korea (Y.J., H.-S.K., R.-S.W., C.H.P., K.-Y.S., K.-A.C., S.K., Y.-H.S.); and Department of Pediatrics, School of Medicine, University of California at San Diego, La Jolla, California (J.-P.L.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) exert anti-inflammatory, analgesic, and antipyretic activities and suppress prostaglandin synthesis by inhibiting cyclooxygenase, an enzyme that catalyzes the formation of prostaglandin precursors from arachidonic acid. Epidemiological observations indicate that the long-term treatment of patients suffering from rheumatoid arthritis with NSAIDs results in reduced risk and delayed onset of Alzheimer's disease. In this study, we investigated the therapeutic potential for Alzheimer's disease of mefenamic acid, a commonly used NSAID that is a cyclooxygenase-1 and 2 inhibitor with only moderate anti-inflammatory properties. We found that mefenamic acid attenuates the neurotoxicities induced by amyloid β peptide (Aβ)1–42 treatment and the expression of a Swedish double mutation (KM595/596NL) of amyloid precursor protein (Swe-APP) or the C-terminal fragments of APP (APP-CTs) in neuronal cells. We also show that mefenamic acid decreases the production of the free radical nitric oxide and reduces cytochrome c release from mitochondria induced by Aβ1–42, Swe-APP, or APP-CTs in neuronal cells. In addition, mefenamic acid up-regulates expression of the antiapoptotic protein Bcl-XL. Moreover, our study demonstrates for the first time that mefenamic acid improves learning and memory impairment in an Aβ1–42-infused Alzheimer's disease rat model. Taking these in vitro and in vivo results together, our study suggests that mefenamic acid could be used as a therapeutic agent in Alzheimer's disease.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 69 (1)
Molecular Pharmacology
Vol. 69, Issue 1
1 Jan 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mefenamic Acid Shows Neuroprotective Effects and Improves Cognitive Impairment in in Vitro and in Vivo Alzheimer's Disease Models
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Mefenamic Acid Shows Neuroprotective Effects and Improves Cognitive Impairment in in Vitro and in Vivo Alzheimer's Disease Models

Yuyoung Joo, Hye-Sun Kim, Ran-Sook Woo, Cheol Hyoung Park, Ki-Young Shin, Jean-Pyo Lee, Keun-A Chang, Seonghan Kim and Yoo-Hun Suh
Molecular Pharmacology January 1, 2006, 69 (1) 76-84; DOI: https://doi.org/10.1124/mol.105.015206

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Mefenamic Acid Shows Neuroprotective Effects and Improves Cognitive Impairment in in Vitro and in Vivo Alzheimer's Disease Models

Yuyoung Joo, Hye-Sun Kim, Ran-Sook Woo, Cheol Hyoung Park, Ki-Young Shin, Jean-Pyo Lee, Keun-A Chang, Seonghan Kim and Yoo-Hun Suh
Molecular Pharmacology January 1, 2006, 69 (1) 76-84; DOI: https://doi.org/10.1124/mol.105.015206
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
  • Benzbromarone relaxes airway smooth muscle via BK activation
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics